Investors in MannKind Corporation (NASDAQ: MNKD) are having another pleasant day. Shares were up 37% as of 10:05 a.m. EDT on Wednesday. That’s quite a bullish move for a single day, but it’s all the more impressive given that the stock also jumped 89% higher on Tuesday.
There isn’t any news today that can justify the huge gain, so the most likely explanation for today’s price is a short squeeze. More than 28 million shares of MannKind’s stock were sold short as of Aug. 15, so millions of shares are probably being purchased today to cover the short in response to yesterday’s news that MannKind has struck up a brand-new collaborative partnership with United Therapeutics (NASDAQ: UTHR).
As a reminder, that deal will net MannKind more than $55 million up front, which should buy the company about six more months of runway. That’s a big enough number to silence the critics who believe that this company is heading for bankruptcy (at least for now).
This short-term price jump is a welcome relief for MannKind’s long-suffering bulls. However, investors need to remember that success still hinges on the company’s ability to turn Afrezza into a commercially viable product. Since there’s a long road ahead of the company on that front, I think that skepticism is still warranted.
10 stocks we like better than MannKind Corporation
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has quadrupled the market.*
David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now… and MannKind Corporation wasn’t one of them! That’s right — they think these 10 stocks are even better buys.
Click here to learn about these picks!
*Stock Advisor returns as of August 6, 2018